BioLineRx presents data at SOBP demonstrating the potential benefit of BL-1020 in improving cognition
BioLineRx Ltd. (TASE: BLRX) announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada May 14-16, 2009.
The ability of BL1020 to improve episodic memory deficits suggests potential for the treatment of cognitive deficits in schizophrenia. EAGLE Phase 2b update- Independent Safety Monitoring Board reviews safety data of first 200 patients.
There are currently no events to display.